Karyopharm announces favorable change in co-primary endpoint for pivotal phase 3 sentry trial in myelofibrosis

Co-primary endpoint changed to absolute total symptom score (abs-tss) from total symptom score improvement of ≥ 50% (tss50) following alignment with the fda spleen volume response rate ≥ 35% (svr35) remains a co-primary endpoint promising improvement in abs-tss and svr35 from phase 1 trial of selinexor in combination with ruxolitinib adds confidence in phase 3 sentry trial proactively increasing total sample size of the sentry trial to approximately 350 patients to further increase the statistical powering; expected top-line data read-out remains in 2h 2025 company to host a conference call today at 8:00 a.m. et featuring drs.
KPTI Ratings Summary
KPTI Quant Ranking